

Editorial

Oral Disease and Diabetes Mellitus: Local Health Links Systemic Health

Hongming Zhang

Department of Endodontology, Temple University, USA

***Corresponding author:** Hongming Zhang, Department of Endodontology, Kornberg School of Dentistry, Temple University, 3223 N. Broad St, Philadelphia, PA 19140, USA, Tel: 215-707-3939; Email: hongming.zhang@temple.edu

Received: May 31, 2014; **Accepted:** June 02, 2014;

Published: June 04, 2014

Diabetes Mellitus (DM or diabetes) is a heterogeneous chronic metabolic disorder with high blood sugar (hyperglycemia) resulting from defects in insulin secretion or insulin action. Type 2 diabetes mellitus (insulin resistance, or called non-insulin dependent diabetes mellitus, NIDDM, T2D) accounts for about 90%. Type 1 diabetes (lack of insulin, also called insulin dependent diabetes mellitus, IDDM or juvenile diabetes, T1D) and gestational diabetes mellitus (insulin resistance during pregnancy, GDM) account for about 10%. DM has been emerging as an epidemic disease around the world. There are 366 million people worldwide suffering from diabetes in 2011, and this number is predicted to increase by about 50% by year 2030 [1]. In the U.S. diabetes affects 25.8 million or 8.3% population [2]. The economic cost of diagnosed diabetes in the U.S. in 2012 is \$245 billion, including \$176 billion in direct costs and \$69 billion in reduced productivity (disability, work loss, premature mortality) [3]. Its complications include retinopathy, nephropathy, neuropathy, cardiovascular disease and impaired wound healing.

Over the past decades oral disease has been recognized as in close connection with the systemic diabetes mellitus particularly among elder people [4-9]. Periodontal Disease (PD) has been acknowledged as the sixth complication of diabetes [10]. Oral mucosal lesions, xerostomia and other oral diseases are also reported in association with diabetes [11-14]. Oral disease is a major public health problem in both developed and developing countries [15-19]. According to the US Centers for Medicare and Medicaid Services report the expenditure for dental services in 2012 is \$110.9 billion and projected to \$167.9 billion in 2020 [20].

Accumulating evidence demonstrates that diabetes mellitus and oral disease have a bidirectional relationship [21-24]. Patients with oral disease have more prevalence of DM, and DM increases the risk for and severity of periodontitis and other oral diseases [25,26]. Treatment of oral diseases can significantly improve the glycemic control of DM patients and vice versa [21,27-29]. The tremendous amount of observations of the link between oral disease and diabetes mellitus deserve great attention in tackling these two highly prevalent and closely related chronic diseases.

People are investigating through pathological and biochemical ways to elucidate the mechanisms that are underlining the local oral

disease and the interrelated systemic diabetes mellitus. Up to date the mechanisms by which oral diseases may affect diabetes mellitus are not well established. Several hypotheses have been postulated to describe the possible manifestations of these two interplaying epidemics.

Pro-inflammation is one mechanism for this pathogenic feed-forward loop [30-32]. Oral inflammation and pathogens and their toxins (especially lipopolysaccharide, LPS) may activate macrophages and T lymphocytes that trigger the production of pro-inflammatory cytokines (such as IL-1, IL-6, TNF- β , lymphotoxin, prostaglandins and high sensitivity C-reactive proteins) [33], enzymes (such as Paraoxonase-1, PON-1) [34] and oxidative stress molecules that have important effects on lipid, glucose and protein metabolism. These pro-inflammatory cytokines have been identified as a potent antagonist to the cell surface insulin-receptor protein needed for proper glucose transport and directly related to the impairing of insulin sensitivity or action. The resistance to insulin action results in the irreversible formation of advanced glycation end-products (AGEs) under hyperglycemic conditions [31]. AGE-RAGE axis has been proposed as playing an important role in tissue destruction and impaired repair in diabetes-associated periodontitis [22]. AGEs impart their pathogenic effects by interaction with their specific cellular receptor for AGE (RAGE) on macrophages and monocytes that induce a hyper-responsive state, leading to enhanced secretion of various proinflammatory cytokines to predispose to chronic tissue inflammation, progressive tissue breakdown, and diminished capacity for tissue repair, thus contributing to periodontitis.

One of the molecules formed by the nonenzymatic addition of glucose is glycated hemoglobin (HbA1c). Researches indicate that levels of HbA1c and fasting blood glucose (FBG) significantly correlated with periodontal health among individuals with T2D [35]. HbA1c within red blood cells (erythrocytes) circulates and persists in the bloodstream for up to 120 days, it forms the basis for a convenient clinical indicator of the degree of glycemic control. Prediabetic conditions, which include impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), might be associated with chronic gingival and/or periodontal inflammation [36-38].

Diabetes mellitus favors the occurrence of oral morbidity through gum's microvascular disorders, the selection and development of an aggressive bacterial plaque and through an exaggerating inflammatory response to the microflora within the oral cavity. *Actinobacillus actinomycetemcomitans*, *Campylobacter rectus*, *Helicobacter pylori*, *Porphyromonas gingivalis*, human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV-1) have been reported as prevailing pathogens in oral diseases [39]. *A. actinomycetemcomitans* is associated with periodontitis in patients with diabetes while *P. gingivalis* in patients without diabetes [40,41].

There are reports demonstrating that collagen molecules are more easily glycosylated under the hyperglycemic conditions, leading to excessive cross-linking, and collagenase is increased in the crevicular fluid of diabetic patients. This resulted in accumulation of abnormally glycosylated, highly cross-linked gingival collagen, thereby adversely affecting normal tissue turnover and healing in diabetic individuals [42-44].

Resistin is recently acknowledged as a biomarker that links periodontal disease with systemic diseases, such as DM. Resistin is a newly discovered adipocytokine and considered as a peptide hormone, initially thought to be produced by adipocytes alone, and later found also produced in abundance by various cells of the immunoinflammatory system, indicating its role in various chronic inflammatory diseases. A three-way relationship has been established between diabetes, obesity and periodontitis [45].

Human β -Defensins (hBDs) have been reported having a strong antibacterial action against various microorganisms, especially periodontal pathogens. hBD-1 and hBD-3 have been shown to be related to DM and periodontal disease [46].

DM can change the oral environment that affects the oral microbiota. That may account for the increased severity of aggressive oral infections and poorer glycemic control in DM patients [47-49].

Many other conditions can predispose and/or facilitate the occurrence of PD, such as smoking and obesity that are linked to diabetes mellitus. The best predictor for severe periodontal disease in subjects with T2D is smoking followed by HbA1c levels. T2D subjects should be informed about the increased risk for periodontal disease when suffering from T2D [50].

There are some controversies among the results of the link between PD and DM. In one report with periodontal treatment as predictor and the actual change in hemoglobin A1c level as the outcome, it showed that none was statistically significant [51]. Another research with Mexican-American population also showed that no statistically significant differences were found in the changes of HbA1c levels between test and control groups. Non-surgical periodontal therapy improved the magnitude of change in periodontal parameters as compared to the control subjects [52]. The causes of the discrepancy among the research results may come from sampling size, bias, analysis method, heterogeneity and the chronic properties of these two epidemic diseases [53].

Although there is a strong body of evidence that supports the relationship between oral health and diabetes, oral health awareness is lacking among patients with diabetes and other health professionals [54-56]. In future directions, there is a real need for larger, prospective, controlled, longitudinal and cross-sectional clinical studies, together with studies of animal models and cells/tissues in vitro [22,54] and emphasizes for more researches to define a clear relationship between these interplaying complications. More importantly this knowledge needs to be informed to the public about this interface, especially for patients with diabetes and/or oral diseases to be aware of the interrelationship of these two chronic epidemics.

We are aware that the mouth is an integral part of the body and as the Chinese saying goes, illness comes from the mouth, we should pay great attention to dental hygiene in order to improve our body

health. Taken together, oral diseases have an adverse impact on the glycemic control of diabetes and diabetes increases the prevalence and severity of oral diseases. This calls for cooperative work between inter-professional health management in the provision of overall health care for patients with oral disease and systemic diabetes.

References

- Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract.* 2011; 94: 311-321.
- Lecka-Czernik B. Safety of Anti-Diabetic Therapies on Bone. *Clin Rev Bone Miner Metab.* 2013; 11: 49-58.
- American Diabetes Association.
- Saremi A, Nelson RG, Tulloch-Reid M, Hanson RL, Sievers ML, Taylor GW, et al. Periodontal disease and mortality in type 2 diabetes. *Diabetes Care.* 2005; 28: 27-32.
- Duarte PM, Neto JB, Casati MZ, Sallum EA, Nociti FH Jr. Diabetes modulates gene expression in the gingival tissues of patients with chronic periodontitis. *Oral Dis.* 2007; 13: 594-599.
- Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. *Nat Rev Endocrinol.* 2011; 7: 738-748.
- Leite RS, Marlow NM, Fernandes JK. Oral health and type 2 diabetes. *Am J Med Sci.* 2013; 345: 271-273.
- DPTT study group, Engebretson S, Gelato M, Hyman L, Michalowicz BS, Schoenfeld E. Design features of the Diabetes and Periodontal Therapy Trial (DPTT): a multicenter randomized single-masked clinical trial testing the effect of nonsurgical periodontal therapy on glycosylated hemoglobin (HbA1c) levels in subjects with type 2 diabetes and chronic periodontitis. *Contemp Clin Trials.* 2013; 36: 515-526.
- Atieh MA, Faggion CM Jr, Seymour GJ. Cytokines in patients with type 2 diabetes and chronic periodontitis: A systematic review and meta-analysis. *Diabetes Res Clin Pract.* 2014; 104: e38-45.
- Lõe H. Periodontal diseases: a brief historical perspective. *Periodontol.* 2000. 1993; 2: 7-12.
- Seyhan M, Ozcan H, Sahin I, Bayram N, Karincioğlu Y, Yücel Y. High prevalence of glucose metabolism disturbance in patients with lichen planus. *Diabetes Res Clin Pract.* 2007; 77: 198-202.
- Vasconcelos BC, Novaes M, Sandrini FA, Maranhão Filho AW, Coimbra LS. Prevalence of oral mucosa lesions in diabetic patients: a preliminary study. *Braz J Otorhinolaryngol.* 2008; 74: 423-428.
- Bastos AS, Leite AR, Spin-Neto R, Nassar PO, Massucato EM, Orrico SR. Diabetes mellitus and oral mucosa alterations: prevalence and risk factors. *Diabetes Res Clin Pract.* 2011; 92: 100-105.
- Ivanovski K, Naumovski V, Kostadinova M, Pesevska S, Drijanska K, Filipce V. Xerostomia and salivary levels of glucose and urea in patients with diabetes. *Prilozi.* 2012; 33: 219-229.
- Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C. The global burden of oral diseases and risks to oral health. *Bull World Health Organ.* 2005; 83: 661-669.
- Albandar JM. Periodontal disease is prevalent among adults in France. *J Evid Based Dent Pract.* 2008; 8: 89-90.
- Kakde S, Bedi R, Verma M. Oral health inequalities: a call for action to improve oral health in India. *Int Dent J.* 2013; 63: 324-328.
- Corbella S, Francetti L, Taschieri S, De Siena F, Fabbro MD. Effect of periodontal treatment on glycemic control of patients with diabetes: A systematic review and meta-analysis. *J Diabetes Investig.* 2013; 4: 502-509.
- Casarin RC, Barbagallo A, Meulman T, Santos VR, Sallum EA, Nociti FH, et al. Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis. *J Periodontol Res.* 2013; 48: 30-36.

20. Centers for Medicare and Medicaid Services.
21. Teeuw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. *Diabetes Care*. 2010; 33: 421-427.
22. Taylor JJ, Preshaw PM, Lalla E. A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes. *J Clin Periodontol*. 2013; 40: S113-134.
23. Borgnakke WS, Ylöstalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. *J Periodontol*. 2013; 84: S135-152.
24. Arora N, Papapanou PN, Rosenbaum M, Jacobs DR Jr, Desvarieux M, Demmer RT. Periodontal infection, impaired fasting glucose and impaired glucose tolerance: results from the Continuous National Health and Nutrition Examination Survey 2009-2010. *J Clin Periodontol*. 2014 [In press].
25. Jimenez M, Hu FB, Marino M, Li Y, Joshipura KJ. Type 2 diabetes mellitus and 20 year incidence of periodontitis and tooth loss. *Diabetes Res Clin Pract*. 2012; 98: 494-500.
26. Tanwir F, Tariq A. Effect of glycemic control on periodontal status. *J Coll Physicians Surg Pak*. 2012; 22: 371-374.
27. Yuan T, Zhang Y, Zhou Y, Wang F, Wang F. Effect of non-surgical periodontal therapy on level of serum soluble intercellular adhesion molecule-1 and glycated hemoglobin A1c in patients with type 2 diabetes and chronic periodontitis. *Hua Xi Kou Qiang Yi Xue Za Zhi*. 2013; 31:415-419.
28. Katagiri S, Nitta H, Nagasawa T, Izumi Y, Kanazawa M, Matsuo A, et al. Effect of glycemic control on periodontitis in type 2 diabetic patients with periodontal disease. *J Diabetes Investig*. 2013; 4: 320-325.
29. Cintra LT, Samuel RO, Facundo AC, Prieto AK, Sumida DH, Bomfim SR, et al. Relationships between oral infections and blood glucose concentrations or HbA1c levels in normal and diabetic rats. *Int Endod J*. 2014; 47: 228-237.
30. Iacopino AM. Periodontitis and diabetes interrelationships: role of inflammation. *Ann Periodontol*. 2001; 6: 125-137.
31. Shim E, Babu JP. Glycated albumin produced in diabetic hyperglycemia promotes monocyte secretion of inflammatory cytokines and bacterial adherence to epithelial cells. *Periodontol Res*. 2014 [In press].
32. Demmer RT, Squillaro A, Papapanou PN, Rosenbaum M, Friedewald WT, Jacobs DR Jr, et al. Periodontal infection, systemic inflammation, and insulin resistance: results from the continuous National Health and Nutrition Examination Survey (NHANES) 1999-2004. *Diabetes Care*. 2012; 35: 2235-2242.
33. Grossi SG. Treatment of periodontal disease and control of diabetes: an assessment of the evidence and need for future research. *Ann Periodontol*. 2001; 6: 138-145.
34. Noack B, Aslanhan Z, Boué J, Petig C, Teige M, Schaper F, et al. Potential association of paraoxonase-, type 2 diabetes mellitus, and periodontitis. *J Periodontol*. 2013; 84: 614-623.
35. Kim EK, Lee SG, Choi YH, Won KC, Moon JS, Merchant AT, et al. Association between diabetes-related factors and clinical periodontal parameters in type-2 diabetes mellitus. *BMC Oral Health*. 2013; 13: 64.
36. Choi YH, McKeown RE, Mayer-Davis EJ, Liese AD, Song KB, et al. Association between periodontitis and impaired fasting glucose and diabetes. *Diabetes Care*. 2011; 34: 381-386.
37. Andriankaja OM, Joshipura K. Potential association between prediabetic conditions and gingival and/or periodontal inflammation. *J Diabetes Investig*. 2014; 5: 108-114.
38. Arora N, Papapanou PN, Rosenbaum M, Jacobs DR Jr, Desvarieux M, Demmer RT. Periodontal infection, impaired fasting glucose and impaired glucose tolerance: results from the Continuous National Health and Nutrition Examination Survey 2009-2010. *J Clin Periodontol*. 2014.
39. Tanner A, Stillman N. Oral and dental infections with anaerobic bacteria: clinical features, predominant pathogens, and treatment. *Clin Infect Dis*. 1993; 16 Suppl 4: S304-309.
40. Silva DG, Stevens RH, Macedo JM, Albano RM, Falabella ME, Fischer RG, et al. Presence of *Helicobacter pylori* in supragingival dental plaque of individuals with periodontal disease and upper gastric diseases. *Arch Oral Biol*. 2010; 55: 896-901.
41. Castrillon CA, Hincapie JP, Yepes FL, Roldan N, Moreno SM, Contreras A, et al. Occurrence of red complex microorganisms and *Aggregatibacter actinomycetemcomitans* in patients with diabetes. *J Investig Clin Dent*. 2013;.
42. Ritchie CS. Mechanistic links between type 2 diabetes and periodontitis. *J Dent*. 2009; 37: S578-579.
43. Ryan ME, Carnu O, Kamer A. The influence of diabetes on the periodontal tissues. *J Am Dent Assoc*. 2003; 134 Spec No: 34S-40S.
44. Daniel R, Gokulanathan S, Shanmugasundaram N, Lakshmi Gandhan M, Kavin T. Diabetes and periodontal disease. *J Pharm Bioallied Sci*. 2012; 4: S280-282.
45. Devanoorkar A, Kathariya R, Guttiganur N, Gopalakrishnan D, Bagchi P. Resistin: a potential biomarker for periodontitis influenced diabetes mellitus and diabetes induced periodontitis. *Dis Markers*. 2014; 2014: 930206.
46. Ertugrul AS, Dikilitas A, Sahin H, Alpaslan N, Bozoglan A, Tekin Y. Gingival crevicular fluid levels of human beta-defensins 1 and 3 in subjects with periodontitis and/or type 2 diabetes mellitus: a cross-sectional study. *J Periodontol Res*. 2013; 48: 475-482.
47. Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q, et al. Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing. *PLoS One*. 2013; 8: e61516.
48. Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, Romero H, Simón-Soro A, Pignatelli M, et al. The oral metagenome in health and disease. *ISME J*. 2012; 6: 46-56.
49. Fouad AF. Diabetes mellitus as a modulating factor of endodontic infections. *J Dent Educ*. 2003; 67: 459-467.
50. Jansson H, Lindholm E, Lindh C, Groop L, Bratthall G. Type 2 diabetes and risk for periodontal disease: a role for dental health awareness. *J Clin Periodontol*. 2006; 33: 408-414.
51. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment improve glycemic control in diabetic patients? A meta-analysis of intervention studies. *J Dent Res*. 2005; 84: 1154-1159.
52. Gay IC, Tran DT, Cavender AC, Weltman R, Chang J, Luckenbach E, et al. The Effect of Periodontal Therapy on Glycemic Control in a Hispanic Population with Type 2 Diabetes: A Randomized Controlled Trial. *J Clin Periodontol*. 2014 [In press].
53. Cullinan MP, Seymour GJ. Periodontal disease and systemic illness: will the evidence ever be enough? *Periodontol 2000*. 2013; 62: 271-286.
54. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. *Cochrane Database Syst Rev*. 2010; CD004714.
55. Lamster Ira B. Diabetes mellitus and oral health: an interprofessional approach. Wiley-Blackwell. 2014.
56. Albert DA, Ward A, Allweiss P, Graves DT, Knowler WC, Kunzel C, et al. Diabetes and oral disease: implications for health professionals. *Ann N Y Acad Sci*. 2012; 1255: 1-15.